You searched for: cisteaminijevega (Slovenska - Engelska)

končni razpolovni čas cisteaminijevega bitartrata je približno 4 ure.
the terminal half-life of cysteamine bitartrate is approximately 4 hours.

ni ustreznih podatkov o uporabi cisteaminijevega bitartrata pri nosečnicah.
there are no adequate data from the use of cysteamine bitartrate in pregnant women.

farmakokinetike cisteaminijevega bitartrata pri posebnih skupinah bolnikov niso proučevali.
the pharmacokinetics of cysteamine bitartrate has not been studied in special populations.

Študij kancerogenosti z gastrorezistentnimi trdimi kapsulami cisteaminijevega bitartrata niso izvedli.
no carcinogenic studies have been conducted with cysteamine bitartrarte gastro-resistant hard capsules.

pri farmacevtski obliki cisteaminijevega bitartrata s takojšnjim sproščanjem je neželene učinke mogoče pričakovati pri približno 35 % bolnikov.
for the immediate-release formulation of cysteamine bitartrate, approximately 35% of patients can be expected to experience adverse reactions.

cisteaminijevega bitartrata se ne sme jemati skupaj s hrano, bogato z maščobami ali beljakovinami, ali z zamrznjeno hrano, kot je sladoled.
cysteamine bitartrate should not be administered with food rich in fat or proteins, or with frozen food like ice-cream.

pri bolnikih, zdravljenih z velikimi odmerki cisteaminijevega bitartrata s takojšnjim sproščanjem ali drugimi cisteaminovimi solmi, so poročali o resnih kožnih lezijah, ki so se izboljšale po zmanjšanju odmerka cisteamina.
there have been reports of serious skin lesions in patients treated with high doses of immediate-release cysteamine bitartrate or other cysteamine salts that have responded to cysteamine dose reduction.

bolniki s cistinozo, ki jemljejo cisteaminijev bitartrat s takojšnjim sproščanjem, lahko preidejo na skupni dnevni odmerek zdravila procysbi, ki ustreza predhodnemu skupnemu dnevnemu odmerku cisteaminijevega bitartrata s takojšnjim sproščanjem.
patients with cystinosis taking immediate-release cysteamine bitartrate may be transferred to a total daily dose of procysbi equal to their previous total daily dose of immediate-release cysteamine bitartrate.

odmerek cisteaminijevega bitartrata s takojšnjim sproščanjem 1,95 grama/m2/dan je povezan z višjo stopnjo prekinitve zdravljenja zaradi nezmožnosti prenašanja zdravila in povečano pojavnostjo neželenih učinkov.
the dose of 1.95 grams/m2/day of immediate-release cysteamine bitartrate has been associated with an increased rate of withdrawal from treatment due to intolerance and an increased incidence of adverse events.

po enkratnem peroralnem odmerku cisteaminijevega bitartrata, ki ustreza 1,05 g proste baze cisteamina, je pri zdravih prostovoljcih povprečen (± sd) čas do dosežene najvišje koncentracije 1,4 (± 0,5) h, najvišja plazemska koncentracija pa znaša 4,0 (± 1,0) µg/ml.
following a single oral dose of cysteamine bitartrate equivalent to 1.05 g of cysteamine free base in healthy volunteers, the mean ( sd) values for the time to peak and peak plasma concentration are 1.4 ( 0.5) hours and 4.0 ( 1.0) µg/ml, respectively.